{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:07:40Z","timestamp":1793909260916,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Decision to undergo risk-reducing mastectomy (RRM) needs to consider several factors, including patient\u2019s preference, surgeon\u2019s preference, family history, and genetic predisposition. The aim of this study was to examine whether preoperative diagnosis of<jats:italic>BRCA1\/2<\/jats:italic>mutation status could influence surgical decision-making in newly diagnosed breast cancer patients. We retrospectively reviewed ipsilateral breast cancer patients with<jats:italic>BRCA1\/2<\/jats:italic>mutation who underwent primary surgery between January 2008 and November 2019 at a single institution in Korea. Of 344 eligible patients, 140 (40.7%) patients were aware of their mutation status \u2018prior to surgery\u2019, while 204 (59.3%) did not. Contralateral RRM rate was significantly higher in the group with<jats:italic>BRCA1\/2<\/jats:italic>mutation status identified \u2018prior to surgery\u2019 compared to the group with mutation status identified \u2018after surgery\u2019 [45.0% (63\/140) vs. 2.0% (4\/204)] (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Reduced turnaround time of<jats:italic>BRCA1\/2<\/jats:italic>testing (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and the use of neoadjuvant chemotherapy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) were associated with<jats:italic>BRCA1\/2<\/jats:italic>mutation status identified prior to surgery. Although not statistically significant, higher incidence of developing contralateral breast cancer for<jats:italic>BRCA1\/2<\/jats:italic>mutation carriers who underwent ipsilateral surgery-only compared to those who underwent contralateral RRM was observed [12.1% (95% CI: 7.7\u201317.7%)] (<jats:italic>p<\/jats:italic>\u2009=\u20090.1618). Preoperative diagnosis of<jats:italic>BRCA1\/2<\/jats:italic>mutation could impact surgical decision-making for breast cancer patients to undergo risk-reducing surgery at the time of initial surgery.<\/jats:p>","DOI":"10.1038\/s41598-021-94195-4","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T10:26:57Z","timestamp":1626776817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Preoperative diagnosis of BRCA1\/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients"],"prefix":"10.1038","volume":"11","author":[{"given":"Jinsun","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geumhee","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inseok","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Noe","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Joo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Min","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"94195_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-018-4824-9","volume":"171","author":"A Liede","year":"2018","unstructured":"Liede, A. et al. Risk-reducing mastectomy rates in the US: A closer examination of the Angelina Jolie effect. Breast Cancer Res. Treat. 171, 435\u2013442 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"94195_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4048\/jbc.2017.20.2.203","volume":"20","author":"J Lee","year":"2017","unstructured":"Lee, J. et al. Influence of the Angelina Jolie announcement and insurance reimbursement on practice patterns for hereditary breast cancer. J. Breast Cancer 20, 203\u2013207 (2017).","journal-title":"J. Breast Cancer"},{"key":"94195_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s13058-014-0442-6","volume":"16","author":"DG Evans","year":"2014","unstructured":"Evans, D. G. et al. The Angelina Jolie effect: How high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 16, 442 (2014).","journal-title":"Breast Cancer Res."},{"key":"94195_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10549-014-2890-1","volume":"144","author":"A Valachis","year":"2014","unstructured":"Valachis, A., Nearchou, A. D. & Lind, P. Surgical management of breast cancer in BRCA-mutation carriers: A systematic review and meta-analysis. Breast Cancer Res. Treat. 144, 443\u2013455 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"94195_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10549-010-0805-3","volume":"124","author":"DM van der Kolk","year":"2010","unstructured":"van der Kolk, D. M. et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: High cancer incidence at older age. Breast Cancer Res. Treat. 124, 643\u2013651 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"94195_CR6","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat, N. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J. Natl. Cancer Inst. 105, 812\u2013822 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"94195_CR7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402\u20132416 (2017).","journal-title":"JAMA"},{"key":"94195_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","volume":"93","author":"TC van Sprundel","year":"2005","unstructured":"van Sprundel, T. C. et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br. J. Cancer 93, 287\u2013292 (2005).","journal-title":"Br. J. Cancer"},{"key":"94195_CR9","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"LC Hartmann","year":"2001","unstructured":"Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 93, 1633\u20131637 (2001).","journal-title":"J. Natl. Cancer Inst."},{"key":"94195_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/SLA.0b013e3181c3c36d","volume":"251","author":"R Kaas","year":"2010","unstructured":"Kaas, R. et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: Very low risk for subsequent breast cancer. Ann. Surg. 251, 488\u2013492 (2010).","journal-title":"Ann. Surg."},{"key":"94195_CR11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/1940-6207.CAPR-09-0130","volume":"3","author":"M Yi","year":"2010","unstructured":"Yi, M. et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prevent. Res. (Phila) 3, 1026\u20131034 (2010).","journal-title":"Cancer Prevent. Res. (Phila)"},{"key":"94195_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13053-017-0071-z","volume":"15","author":"S Yadav","year":"2017","unstructured":"Yadav, S., Reeves, A., Campian, S., Sufka, A. & Zakalik, D. Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: A retrospective cohort analysis. Hered. Cancer Clin. Pract. 15, 11 (2017).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"94195_CR13","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1245\/s10434-009-0641-z","volume":"16","author":"AK Arrington","year":"2009","unstructured":"Arrington, A. K., Jarosek, S. L., Virnig, B. A., Habermann, E. B. & Tuttle, T. M. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann. Surg. Oncol. 16, 2697\u20132704 (2009).","journal-title":"Ann. Surg. Oncol."},{"key":"94195_CR14","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1245\/s10434-016-5328-7","volume":"23","author":"A Chiba","year":"2016","unstructured":"Chiba, A. et al. Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1\/BRCA2 mutation carriers with breast cancer. Ann. Surg. Oncol. 23, 3232\u20133238 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"94195_CR15","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1007\/s00268-017-4342-7","volume":"42","author":"S Park","year":"2018","unstructured":"Park, S. et al. Genetic diagnosis before surgery has an impact on surgical decision in BRCA mutation carriers with breast cancer. World J. Surg. 42, 1384\u20131390 (2018).","journal-title":"World J. Surg."},{"key":"94195_CR16","unstructured":"National Human Genome Research Institute. Breast Cancer Information Core. https:\/\/research.nhgri.nih.gov\/bic\/. Accessed 1 Oct 2020."},{"key":"94195_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ygyno.2014.05.028","volume":"134","author":"E Lokich","year":"2014","unstructured":"Lokich, E. et al. Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol 134, 326\u2013330 (2014).","journal-title":"Gynecol Oncol"},{"key":"94195_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10689-015-9788-x","volume":"14","author":"MR Wevers","year":"2015","unstructured":"Wevers, M. R. et al. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1\/2 mutation: Retrospective data from the Dutch HEBON study. Fam. Cancer 14, 355\u2013363 (2015).","journal-title":"Fam. Cancer"},{"key":"94195_CR19","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1200\/JCO.2017.76.2781","volume":"36","author":"N Colombo","year":"2018","unstructured":"Colombo, N. et al. Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer. J. Clin. Oncol. 36, 1300\u20131307 (2018).","journal-title":"J. Clin. Oncol."},{"key":"94195_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4174\/astr.2017.92.5.331","volume":"92","author":"HS Park","year":"2017","unstructured":"Park, H. S. et al. Next-generation sequencing of BRCA1\/2 in breast cancer patients: Potential effects on clinical decision-making using rapid, high-accuracy genetic results. Ann. Surg. Treat. Res. 92, 331\u2013339 (2017).","journal-title":"Ann. Surg. Treat. Res."},{"key":"94195_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000441714","volume":"19","author":"S Nakamura","year":"2016","unstructured":"Nakamura, S. et al. Current status of the management of hereditary breast and ovarian cancer in Asia: First report by the Asian BRCA consortium. Public Health Genomics 19, 53\u201360 (2016).","journal-title":"Public Health Genomics"},{"key":"94195_CR22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jamaoncol.2015.3048","volume":"1","author":"J Armstrong","year":"2015","unstructured":"Armstrong, J. et al. Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: The ABOUT study. JAMA Oncol. 1, 1251\u20131260 (2015).","journal-title":"JAMA Oncol."},{"key":"94195_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/bjc.2013.805","volume":"110","author":"MR Wevers","year":"2014","unstructured":"Wevers, M. R. et al. Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: Findings from a randomised controlled trial. Br. J. Cancer 110, 1081\u20131087 (2014).","journal-title":"Br. J. Cancer"},{"key":"94195_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10549-018-4773-3","volume":"170","author":"MD Schwartz","year":"2018","unstructured":"Schwartz, M. D. et al. Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients. Breast Cancer Res. Treat. 170, 517\u2013524 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"94195_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/annonc\/mdt422","volume":"25","author":"L Cortesi","year":"2014","unstructured":"Cortesi, L. et al. A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1\/2-positive Italian women. Ann. Oncol. 25, 57\u201363 (2014).","journal-title":"Ann. Oncol."},{"key":"94195_CR26","doi-asserted-by":"crossref","unstructured":"Metcalfe, K. et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: Retrospective analysis. BMJ 348, g226 (2014).","DOI":"10.1136\/bmj.g226"},{"key":"94195_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10549-011-1479-1","volume":"128","author":"SA Narod","year":"2011","unstructured":"Narod, S. A. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res. Treat. 128, 581\u2013583 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"94195_CR28","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.ejca.2005.02.037","volume":"41","author":"YM Kirova","year":"2005","unstructured":"Kirova, Y. M. et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur. J. Cancer 41, 2304\u20132311 (2005).","journal-title":"Eur. J. Cancer"},{"key":"94195_CR29","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2000.18.19.3360","volume":"18","author":"LJ Pierce","year":"2000","unstructured":"Pierce, L. J. et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1\/2 mutations. J. Clin. Oncol. 18, 3360\u20133369 (2000).","journal-title":"J. Clin. Oncol."},{"key":"94195_CR30","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/S0140-6736(02)08434-9","volume":"359","author":"BG Haffty","year":"2002","unstructured":"Haffty, B. G. et al. Outcome of conservatively managed early-onset breast cancer by BRCA1\/2 status. Lancet 359, 1471\u20131477 (2002).","journal-title":"Lancet"},{"key":"94195_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/jjco\/hyz147","volume":"50","author":"JM Ryu","year":"2020","unstructured":"Ryu, J. M. et al. Prognosis of BRCA1\/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors. Jpn. J. Clin. Oncol. 50, 104\u2013113 (2020).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"94195_CR32","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","volume":"22","author":"X Li","year":"2016","unstructured":"Li, X. et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: A meta-analysis and systematic review. Clin. Cancer Res. 22, 3971\u20133981 (2016).","journal-title":"Clin. Cancer Res."},{"key":"94195_CR33","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","volume":"136","author":"BA Heemskerk-Gerritsen","year":"2015","unstructured":"Heemskerk-Gerritsen, B. A. et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. Int. J. Cancer. 136, 668\u2013677 (2015).","journal-title":"Int. J. Cancer."},{"key":"94195_CR34","doi-asserted-by":"crossref","unstructured":"Carbine, N. E., Lostumbo, L., Wallace, J. & Ko, H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst. Rev. 4, CD002748 (2018).","DOI":"10.1002\/14651858.CD002748.pub4"},{"key":"94195_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/14737140.2020.1732213","volume":"20","author":"G Montagna","year":"2020","unstructured":"Montagna, G. & Morrow, M. Contralateral prophylactic mastectomy in breast cancer: What to discuss with patients. Expert Rev. Anticancer Ther. 20, 159\u2013166 (2020).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"94195_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10549-019-05440-4","volume":"179","author":"P Neven","year":"2020","unstructured":"Neven, P. et al. Risk-reducing mastectomy in BRCA carriers: Survival is not the issue. Breast Cancer Res. Treat. 179, 251\u2013252 (2020).","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94195-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94195-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94195-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T07:37:24Z","timestamp":1699256244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94195-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94195"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94195-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"21 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14747"}}